New combo therapy aims to boost lung cancer treatment
NCT ID NCT07543172
First seen Apr 28, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted pills (sotorasib or adagrasib) can help people with advanced KRAS G12C-mutated lung cancer live longer without their disease getting worse. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The goal is to see if the vaccine boosts the immune system to fight cancer more effectively alongside the targeted therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III LUNG CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.